Quest Diagnostics Introduces BRCAvantage Plus™, Providing New Choices in Genetic Breast Cancer Risk Testing
BRCAvantage Plus is the first major line extension to BRCAvantage, a suite of lab-developed tests for assessing BRCA1 and BRCA2 gene mutations launched in
"BRCAvantage Plus reflects our commitment to giving physicians and patients access to clinically important diagnostic insights into cancer risk," said
A key feature of BRCAvantage Plus is that physicians can order single gene tests as well as a comprehensive panel, depending on the specific clinical and family history, promoting personalized care. An additional "reflex" option automatically tests the five non-BRCA genes in cases where initial BRCA1 and BRCA2 mutation testing produces a negative result.
"In the era of precision medicine, the one-size-fits-all approach is no longer valid," added Dr. Cohen. "By giving physicians choice in testing, BRCAvantage Plus will enable physicians to personalize testing. This is important not only to reduce unnecessary utilization, but also to minimize the potential for delivering information which is not useful or may even create uncertainty in cases where additional testing is not warranted for an individual."
Other unique capabilities of BRCAvantage Plus include:
- Based on the most advanced technologies and scientific knowledge. The BRCAvantage family of services is based on next-generation gene sequencing and multiplex ligation-dependent probe amplification, for analytical sensitivity and specificity of over 99.99% in the company's assay validation study. In addition, identified variants are cross referenced with mutational databases to promote reliable clinical interpretation. Quest is also participating in ongoing collaborative studies to further the understanding of specific mutations together with leading academic medical centers, including
Memorial Sloan Kettering Cancer Centerin New York.
- Access to expert genetic counselors to guide physicians and patients through the risk assessment process. A national survey by
Quest Diagnosticsand Harris Interactive found significant confusion among women polled about BRCA testing, with 82 percent claiming they would not know what to do with a positive BRCA gene test result if they received one. Quest Diagnosticsencourages patients to consult a genetic counselor as well as their physician to understand the clinical need for and medical significance of all genetic cancer-risk tests. As part of the BRCAvantage service, Quest helps patients identify a non-Quest employed genetic counselor for consultation. Physicians may consult a Quest Diagnosticsgenetic counselor for assistance in test selection and interpretation.
- Pre-authorization support. Through its relationships with health plans across
the United States, Quest Diagnosticshelps patients identify if BRCAvantage testing is covered by their individual plan.
- National access to testing. After a physician orders a test, patients can submit blood specimens for testing at Quest's about 2,000 patient service centers located across
the United States, for geographic convenience unmatched by any other BRCA test provider.
"When it comes to genetic testing for cancer risk, a test result alone is not enough. Every patient deserves personalized support as she or he grapples with highly personal, life changing decisions," said
BRCAvantage Plus is not a general screening test. It may be appropriate for individuals who have a personal history of breast cancer and/or a family history consistent with hereditary breast cancer or a variety of other inherited genetic syndromes. Some individuals may be at higher risk for inherited breast cancers, including those of Ashkenazi Jewish heritage and with a personal and family history of breast and ovarian cancers at age 45 or younger.